SI-BONE Inc

SI BONE unveiled a broader medtech portfolio at the Morgan Stanley Healthcare Conference and plans to drive growth beyond sacroiliac joint treatment into spinal, trauma and interventional markets. In the second quarter, global revenue rose 15% and the base of active physicians increased 19% to about 720; adjusted EBITDA improved by roughly 180% and operating cash flow turned positive at just under $1 million. The company is accelerating product rollouts (Granite, TNT, iFuse INTRA) and plans a first spinal fusion device with an alpha launch in Q4 2024, plus one to two new products annually. Improved reimbursement should increase profitability, including new Granite DRGs from October 1, 2026, and potential NTAP support for a third Breakthrough Device from October 1, 2027. » Mere på de.investing.com

SI-BONE reported Q1 2026 revenue of $52.6m (+11.2%) and adjusted EBITDA of $2.5m, a 440% improvement year-over-year. The active physician base rose 17.3% to a record 1,650 doctors, and procedure volume in the US grew by 8%. The company raised its full-year revenue guidance to $230–233m and expects a gross margin of around 79%; cash stands at $144.7m. Despite progress, a net loss of $4.3m remains, and management highlights risks related to market penetration, reimbursements, and production capacity. » Mere på de.investing.com

Si-Bone reported Q1 2026 earnings per share of -$0.10, beating the consensus expectation of -$0.19. Revenue was $52.6 million (+11.2% y/y), missing the estimate of $52.85 million only slightly. Gross margin remained high at 79.8%, adjusted EBITDA rose to $2.5 million (+440%), and the stock climbed 1.79% in after-hours trading. Management raised the full-year guidance and expects accelerated revenue growth. » Mere på de.investing.com